Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :16632343
Publication Date : //

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.


Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS, Leuprolide 22.5 mg depot) ceasing treatment after 9 months if PSA <4 ng/ml, and restarting when PSA >20 ng/ml. QOL was assessed every 3 months for 30 months using the EORTC QLQ-C30 and EORTC QLQ-PR25 module. Data completion for the whole study was 90%. At baseline, our cohort was less symptomatic and had better function than the EORTC reference cohort, which may be related to a shift in clinical practice with time. Testosterone suppression (AS) lead to a significant reduction in global HQOL and deterioration in most function and symptom scales. During the off period, there was a trend of progressive improvement in HQOL that paralleled testosterone recovery but was slower than the rate of deterioration during the treatment phase. Maximum recovery of HQOL occurred most frequently by months 9-12. Testosterone recovery was slower and less complete in older men, and lead to concomitant poorer HOQL recovery. Whilst the magnitude of mean change to scale scores was small, there was a consistent and simultaneous deterioration during maximal androgen blockade (MAB) and improvement during androgen recovery. Older men are more likely to show an impaired testosterone recovery, and this was paralleled by a slower HQOL recovery. Newer methods of analysis to describe results in a way that has meaning to the individual patient are warranted.

Authors : Spry N A , Kristjanson L , Hooton B , Hayden L , Neerhut G , Gurney H , Corica T , Korbel E , Weinstein S , McCaul K ,

Related products :

Catalog number Product name Quantity
orb61223 Bicalutamide Bicalutamide (marketed as Casodex, Cosudex, Calutide, Kalumid) is an oral non-steroidal anti-androgen used in the treatment of prostate cancer and hirsutism. For research use only. 100 mg
30-204 Retinoids exert biologic effects such as potent growth inhibitory and cell differentiation activities and are used in the treatment of hyperproliferative dermatological diseases. These effects are med 0.1 mg
orb60893 Matrine((+)-Matrine) Matrine((+)-Matrine) is an alkaloid found in plants from the Sophora family. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opio 50 mg
EIAAB40264 Homo sapiens,Human,Metalloreductase STEAP2,PCANAP1,Prostate cancer-associated protein 1,Protein upregulated in metastatic prostate cancer,PUMPCn,Six-transmembrane epithelial antigen of prostate 2,SixT
orb60366 Isotretinoin It was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more. For research use only. 1 g
26-851 IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs w 0.05 mg
Prostate - PRC481 Prostate cancer tissue array contains 17 cases of pancreatic tumors and 7 cases of normal and reactive prostate tissues. 2mm
PR207b High_density prostate cancer (1_4 grade) and normal prostate tissue array, 70 cases_208 cores
25-042 The homeodomain-containing transcription factor NKX3-1 is a putative prostate tumor suppressor that is expressed in a largely prostate-specific and androgen-regulated manner. Loss of NKX3-1 protein ex 0.05 mg
PR721 Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores
PR208 High_density (70 cases_208 cores), multiple prostate cancer (1_4 grade), normal prostate and placenta tissue array
PR2085b High_density (208 core) prostate adenocarcinoma (I_4 grade) and normal prostate (from autopsy and cancer adjacent) tissue BLOCK
PR2085a High_density (114 cases_208 cores) prostate adenocarcinoma (I_4 grade) and normal prostate (from autopsy and cancer adjacent) tissue array
PR721 Prostate cancer normal prostate tissue array with TNM, grade and Gleason scores, 24 cases_72 cores; ihc Anti-Actin confirmed
PR481 Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores
PR207b High-density prostate cancer (1-4 grade) and normal prostate tissue array, 70 cases_208 cores, replaced by PR208; ihc P504S confirmed
EIAAB30443 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,Aprin,As3,Pds5b,Rat,Rattus norvegicus,Sister chromatid cohesion protein PDS5 homolog B
EIAAB30441 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,Aprin,As3,Kiaa0979,Mouse,Mus musculus,Pds5b,Sister chromatid cohesion protein PDS5 homol
T191 Prostate cancer test tissue array, with normal prostate control tissues, including TNM, clinical stage and pathology grade, 6 cases_24 cores
EIAAB30444 Androgen-induced proliferation inhibitor,Androgen-induced prostate proliferative shutoff-associated protein AS3,APRIN,AS3,Homo sapiens,Human,KIAA0979,PDS5B,Sister chromatid cohesion protein PDS5 homol
PR481 Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases_48 cores, with grades, stages and Gleason scores; ihc Anti-Actin confirmed
PR208 High-density prostate cancer tissue array(1-4 grade), normal prostate and placenta (as control), 70 cases_208 cores, replacing PR207b; ihc P504S confirmed
orb61248 GDC-0449 Vismodegib is an investigational drug for the treatment of various types of cancer. For research use only. 50 mg
PR807a Prostate cancer, hyperplasia and normal tissue array, including TNM and pathology grade, 79 cases_80 cores, replacing PR807; ihc Anti-Prostate Specific Antigen (PSA) confirmed
EIAAB29917 Castration-induced prostatic apoptosis-related protein 1,Cipar1,CIPAR-1,Parm1,PARM-1,Prostate androgen-regulated mucin-like protein 1 homolog,Prostatic androgen-repressed message 1 protein,Rat,Rattus


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur